The Ethnopharmacology of Atypical Antipsychotics

CNS Spectrums

Volumn 10, Issue S2, 2005, Pages 6-12

  Bradford, L Dianne ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011501413     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900026559     Document Type: Article

References (78)

1. Scordo, MG, Spina, E, Romeo, P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol. 2000; 56: 679–683.
2. Schillevoort, I, de Boer, A, van der Weide, J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002; 12: 235–240.
3. Gonzalez, FJ. The molecular biology of cytochrome P450s. Pharmacol Rev. 1989; 40: 243–288.
4. Brockmoller, J, Kirchheiner, J, Meisel, C, Roots, I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics. 2000; 1: 125–151.
5. Eichelbaum, M, Gross, AS. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects. Pharmacol Ther. 1990; 46: 377–394.
6. Wilkinson, GR, Guengerich, FP, Branch, RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989; 43: 53–76.
7. Wood, AJ, Zhou, HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991; 20: 350–373.
8. Kalow, W. Interethnic variation of drug metabolism. TiPS. 1991; 12: 102–107.
9. Gaedigk, A, Bradford, LD, Marcucci, KA, Leeder, JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002; 72: 76–89.
10. Hardman, JG, Limbird, LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996.
11. Physician’s Desk Reference. 2003. 57th ed. Montvale, NJ: Medical Economics.
12. Bradford, LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3: 229–243.
13. Bradford, LD, Gaedigk, A, Leeder, JS. High frequency of CYP2D6 poor and “intermediate” metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998; 34: 797–804.
14. Wan, Y-J Y, Poland, RE, Han, G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. Pharmacogenetics. 2001; 11: 489–499.
15. Mendoza, R, Wan, Y-J, Poland, RE, et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther. 2001; 70: 552–560.
16. Gaedigk, A, Gotschall, RR, Forbes, NS, Simon, SD, Kearns, GL, Leeder, JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999; 9: 669–682.
17. Bock, KW, Schrenk, D, Foster, A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994; 4: 209–218.
18. Lin, KM, Anderson, D, Poland, RE. Ethnicity and psychopharmacology. Bridging the gap. Psychiatr Clin North Am. 1995; 18: 635–647.
19. Tateishi, T, Chida, M, Ariyoshi, N, Mizorogi, Y, Kamataki, T, Kobayashi, S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999; 65: 570–575.
20. Dahl-Puustinen, M-L, Liden, A, Alm, C, Nordin, C, Bertilsson, L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther. 1989; 46: 78–81.
21. Dahl, ML, Ekqvist, B, Widen, J, Bertilsson, L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand. 1991; 84: 99–102.
22. von Bahr, C, Movin, G, Nordin, C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991; 49: 234–240.
23. Llerena, A, Alm, C, Dahl, ML, Ekqvist, B, Bertilsson, L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992; 14: 92–97.
24. Llerena, A, Dahl, ML, Ekqvist, B, Bertilsson, L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992; 14: 261–264.
25. Berecz, R, de la Rubia, A, Dorado, P, Fernandez-Salguero, P, Dahl, M-L, Llerena, A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003; 59: 45–50.
26. Llerena, A, Berecz, R, de la Rubia, A, Norberto, MJ, Benitez, J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit. 2000; 22: 397–401.
27. Linnet, K, Wiborg, O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996; 60: 41–47.
28. Linnet, K, Wiborg, O. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit. 1996; 18: 629–634.
29. Jerling, M, Dahl, M-L, Aberg-Wistedt, A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther. 1996; 59: 423–428.
30. Jaanson, P, Marandi, T, Kiivet, R-A, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 gentoype. Psychopharmacology. 2002; 162: 67–73.
31. Eap, CB, Guentert, TW, Schaublin-Loidl, M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther. 1996; 59: 322–331.
32. Baumann, P, Meyer, JW, Amey, M, et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992; 14: 1–8.
33. Abilify® [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2004.
34. Huang, M-L, Van Peer, A, Woestenborghs, R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993; 54: 257–268.
35. Ereshefsky, L, Lacombe, S. Pharmacological profile of risperidone. Can J Psychiatry. 1993; 38(suppl 3):S80–S88.
36. Scordo, MG, Spina, E, Facciola, G, Avenoso, A, Johansson, I, Dahl, M-L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999; 147: 300–305.
37. Berecz, R, Llerena, A, de la Rubia, A, et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry. 2002; 35: 231–234.
38. Yasui-Furukori, N, Hidestrand, M, Spina, E, Facciola, G, Scordo, MG, Tybring, G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metabol Dispos. 2001; 29: 1263–1268.
39. Haag, S, Spigset, O, Lakso, HA, Dahlqvist, R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol. 2001; 57: 493–497.
40. Lin, K-M, Finder, E. Neuroleptic dosage for Asians. Am J Psychiatry. 1983; 4: 490–491.
41. Yamamoto, J, Fung, D, Lo, S, Reece, S. Psychopharmacology for Asian Americans and Pacific Islanders. Psychopharmacol Bull. 1979; 15: 29–31.
42. Potkin, SG, Shen, Y, Pardes, H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res. 1984; 12: 167–172.
43. Suzuki, A, Otani, K, Mihara, K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 1997; 7: 415–418.
44. Mihara, K, Suzuki, A, Kondo, T, et al. Effect of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999; 65: 291–294.
45. Someya, T, Suzuki, Y, Shimoda, K, et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psych Clin Neurosci. 1999; 53: 593–597.
46. Roh, H-K, Chung, J-Y, Oh, D-Y, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol. 2001; 52: 265–271.
47. Ohara, K, Tanabu, S, Ishibashi, K, Ikemoto, K, Yoshida, K, Shibuya, H. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 347–350.
48. Yasui-Furukori, N, Kondo, T, Mihara, K, et al. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol. 2002; 42: 1083–1088.
49. Lane, H-Y, Hu, O Y-P, Jann, MW, Deng, H-C, Lin, H-N, Chang, W-H. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatr Res. 1997; 69: 105–111.
50. Shibata, N, Ohnuma, T, Baba, H, Shimada, H, Takahashi, T, Arai, H. Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. Psychiatr Genet. 1999; 9: 145–148.
51. Shimoda, K, Morita, S, Yokono, A, et al. CYP2D6*10 alleles are not the determinant of plasma haloperidol concentrations in Asian patients. Ther Drug Monit. 2000; 22: 392–396.
52. Roh, H-K, Kim, C-E, Chung, W-G, Park, C-S, Svensson, J-O, Bertilsson, L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001; 57: 671–675.
53. Pollock, BG, Mulsant, BH, Sweet, RA, Rosen, J, Altieri, LP, Perel, JM. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull. 1995; 31: 327–332.
54. Arthur, H, Dahl, M-L, Siwers, B, Sjogvist, F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995; 15: 211–216.
55. Vandel, P, Haffen, E, Vandel, S, et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol. 1999; 55: 659–665.
56. Ellingrod, VL, Schultz, SK, Arndt, S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal movement scale (AIMS) score. Psychiatr Genet. 2000; 10: 9–11.
57. Ellingrod, VL, Schultz, SK, Arndt, S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy. 2002; 22: 1416–1419.
58. Andreassen, OA, MacEwan, T, Gulbrandsen, A-K, McCreadie, RG, Steen, VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology. 1997; 131: 174–179.
59. Armstrong, M, Daly, AK, Blennerhassett, R, Ferrier, N, Idle, JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry. 1997; 170: 23–26.
60. Lohmann, PL, Bagli, M, Krauss, H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry. 2003; 36: 73–78.
61. Kapitany, T, Meszaros, K, Lenzinger, E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Res. 1998; 32: 101–106.
62. Spina, E, Ancione, M, Di Rosa, AE, Meduri, M, Caputi, AP. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol. 1992; 42: 347–348.
63. Topic, E, Stefanovic, M, Ivanisevic, AM, Blazinic, F, Culav, J, Skocilic, A. CYP2D6 genotyping in patients on psychoactive drug therapy. Clin Chem Lab Med. 2000; 38: 921–927.
64. Binder, RL, Levy, R. Extrapyramidal reactions in Asians. Am J Psychiatry. 1981; 138: 1243–1244.
65. Binder, RL, Kazamatsuri, H, Nishimura, T, McNiel, DE. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry. 1987; 144: 1494–1496.
66. Sramek, JJ, Sayles, MA, Simpson, GM. Neuroleptic dosage for Asians: a failure to replicate. Am J Psychiatry. 1986; 143: 535–536.
67. Lam, LCW, Garcia-Barcelo, MM, Ungvari, GS, et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry. 2001; 34: 238–241.
68. Nikoloff, D, Shim, J-C, Fairchild, M, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J. 2002; 2: 400–407.
69. Strakowski, SM, Shelton, RC, Kolbrener, ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry. 1993; 54: 96–102.
70. Lawson, WB, Hepler, N, Holladay, J, Cuffel, B. Race as a factor in inpatient and outpatient admissions and diagnosis. Hosp Comm Psychiatry. 1994; 45: 72–74.
71. DelBello, MP, Lopez-Larson, MP, Soutullo, CA, Strakowski, SM. Effects of race on psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2001; 11: 95–103.
72. Opolka, JL, Rascati, K, Brown, CM, Gibson, JP. Ethnicity and schizophrenia medication choice. Presented at the Annual Meeting for the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR 551.
73. Tami, M, et al. Schizophrenia care and the assessment program: treatment by race. Presented at the Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, PA. Abstract NR 360.
74. Morganstern, H, Glazer, WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry. 1993; 50: 723–733.
75. este, DV, Lindamer, LA, Evans, J, Lacro, JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull. 1996; 32: 243–251.
76. Reynolds, GP, Zhang, Z-J, Zhang, X-B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002; 359: 2086–2087.
77. Ellingrod, VL, Miller, D, Schultz, SK, Wehring, H, Arndt, S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet. 2002; 12: 55–58.
78. Gaedigk, A, Ndjountche, L, Gaedigk, R, Leeder, JS, Bradford, LD. Discovery of novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther. 2003; 73: 575–576.